Loading…
Loading…
EGRX does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for EGRX and 80,000+ other tickers.
See exactly how EGRX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for EGRX and 80,000+ other tickers.
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company’s product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant…
Profitability This table compares Galera Therapeutics and Eagle Pharmaceuticals' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Galera Therapeutics N/A N/A -99.34% Eagle Pharmaceuticals N/A N/A N/A Earnings and Valuation This table compares Galera Therapeutics and Eagle Pharmaceuticals"s top-line revenue, earnings per share and valuation. Gross
Eagle Pharmaceuticals (NASDAQ: EGRX - Get Free Report) and Indivior (OTCMKTS:INVVY - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and profitability. Analyst Ratings This is a breakdown of recent recommendations
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX - Get Free Report) shares passed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $0.26 and traded as high as $0.3411. Eagle Pharmaceuticals shares last traded at $0.3411, with a volume of 104 shares. Eagle Pharmaceuticals Stock Performance The company has
WOODCLIFF LAKE, N.J., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the divestiture of the marketing authorization for Barhemsys (amisulpride) in the U.S. to LXO Group, Paris, France.